Dr. Khan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2799 West Grand Boulevard
Detroit, MI 48208Phone+1 313-916-1841
Education & Training
University of MichiganFellowship, Hematology and Medical Oncology, 2005 - 2008- University of MichiganResidency, Internal Medicine, 1999 - 2002
Kilpauk Medical CollegeClass of 1998
Certifications & Licensure
MI State Medical License 2002 - 2026
OH State Medical License 2001 - 2002- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Futibatinib in Patients With Specific FGFR Aberrations Start of enrollment: 2020 Aug 24
- Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors Start of enrollment: 2023 Jul 13
Roles: Principal Investigator
Publications & Presentations
PubMed
- 186 citationsDesigning a broad-spectrum integrative approach for cancer prevention and treatmentKeith I. Block, Charlotte Gyllenhaal, Leroy Lowe, Amedeo Amedei, A.R.M. Ruhul Amin
Seminars in Cancer Biology. 2015-12-01 - 216 citationsPilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic AdenocarcinomaEdward J. Kim, Vaibhav Sahai, Ethan V. Abel, Kent A. Griffith, Joel K. Greenson
Clinical Cancer Research. 2014-12-01 - 80 citationsCaveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic CancerMoumita Chatterjee, Edgar Ben-Josef, Dafydd G. Thomas, Meredith A. Morgan, Mark M. Zalupski
Scientific Reports. 2015-06-12
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
